• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Disulfide- and terminal alkyne-functionalized magnetic silica particles for enrichment of azido glycopeptides?
  Sheng Wang,Wenxian Xie,Xiu Zhang,Xia Zou,Yan Zhang Chem. Commun., 2012,48, 5907-5909
• 3. Fe3O4@SiO2 core–shell nanoparticles for biomedical purposes: adverse effects on blood cells?
  C. Achilli,G. F. Guidetti,A. Ciana,D. Capsoni,G. Minetti Biomater. Sci., 2016,4, 1417-1421
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Secondary amines

Research Briefing on N*1*-Adamantan-1-yl-hexane-1,6-diamine (CAS: 400073-86-1) in Chemical Biology and Pharmaceutical Applications

N*1*-Adamantan-1-yl-hexane-1,6-diamine (CAS: 400073-86-1) is a structurally unique compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its adamantane moiety and hexane-1,6-diamine backbone, exhibits promising potential in various therapeutic applications, including antiviral, antibacterial, and neurodegenerative disease treatments. Recent studies have focused on its synthesis, mechanism of action, and biological activity, providing valuable insights into its pharmacological properties.

One of the key areas of research involving N*1*-Adamantan-1-yl-hexane-1,6-diamine is its role as a potential antiviral agent. The adamantane group is known for its ability to inhibit viral replication, particularly in influenza A viruses. Recent in vitro studies have demonstrated that this compound exhibits enhanced efficacy compared to traditional adamantane derivatives, possibly due to its improved membrane permeability and binding affinity to viral proteins. These findings suggest that N*1*-Adamantan-1-yl-hexane-1,6-diamine could serve as a lead compound for the development of next-generation antiviral drugs.

In addition to its antiviral properties, N*1*-Adamantan-1-yl-hexane-1,6-diamine has shown promise in the treatment of bacterial infections. Research indicates that the compound disrupts bacterial cell membranes, leading to cell lysis and death. This mechanism is particularly effective against Gram-positive bacteria, including drug-resistant strains such as MRSA. The hexane-1,6-diamine moiety is believed to enhance the compound's interaction with bacterial membranes, making it a potential candidate for novel antibiotic development.

Another exciting avenue of research explores the neuroprotective effects of N*1*-Adamantan-1-yl-hexane-1,6-diamine. Preliminary studies suggest that the compound may mitigate oxidative stress and inflammation in neuronal cells, which are key factors in neurodegenerative diseases like Alzheimer's and Parkinson's. The adamantane group's ability to cross the blood-brain barrier further enhances its therapeutic potential in this context. Ongoing research aims to elucidate the precise molecular pathways involved in these neuroprotective effects.

The synthesis and optimization of N*1*-Adamantan-1-yl-hexane-1,6-diamine have also been a focal point of recent studies. Researchers have developed novel synthetic routes to improve yield and purity, while also exploring structural modifications to enhance bioavailability and reduce toxicity. These efforts are critical for advancing the compound from the laboratory to clinical applications. Computational modeling and structure-activity relationship (SAR) studies have provided valuable guidance in this optimization process.

In conclusion, N*1*-Adamantan-1-yl-hexane-1,6-diamine (CAS: 400073-86-1) represents a versatile and promising compound in chemical biology and pharmaceutical research. Its multifaceted biological activities, ranging from antiviral and antibacterial effects to neuroprotection, highlight its potential as a therapeutic agent. Continued research and development efforts are essential to fully realize its clinical applications and address current challenges such as toxicity and drug resistance. This compound exemplifies the innovative approaches being pursued in the quest for new and effective treatments in the biomedical field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)